Open an account

Elite Pharmaceuticals

ELTP · OTC

$0.2452−$0.0055 (−2.19%)TodayMarket closed ·
Prev close $0.2507

About ELTP

Elite Pharmaceuticals, Inc. engages in the provision of development and manufacture of pharmacological abuse-deterrent opioid products. The company is headquartered in Northvale, New Jersey and currently employs 68 full-time employees. The company went IPO on 2014-02-20. The firm specializes in developing and manufacturing oral, controlled-release drug products. The company owns multiple generic products which has been licensed to Prasco, LLC and TAGI Pharma. The Company’s segments include Abbreviated New Drug Applications (ANDA) and New Drug Application (NDA). The Company’s products include Phentermine HCl 37.5mg tablets, Loxapine Succinate 5mg, 10mg, 25mg and 50gm capsules, Phentermine HCl 15mg and 30mg capsules, Naltrexone HCl 50mg tablets, Dantrolene Sodium Capsules 25mg, 50mg and 100mg, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Immediate Release 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg and 30mg tablets, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules and others.

Employees
68
Headquarters
Northvale, New Jersey
Listed
Feb 20, 2014
Sector
Health Care
Industry
Pharmaceuticals
Website
elitepharma.com

ELTP key statistics

Market cap
270.10M
Price-earnings ratio
6.27
Dividend yield
—
Average volume
762.83K
Volume
742.32K
Open price
$0.2506
High today
$0.2589
Low today
$0.2385
52 Week high
$0.69
52 Week low
$0.213

Elite Pharmaceuticals (ELTP) at a glance

Elite Pharmaceuticals (ELTP) last traded at $0.2452, with a market cap of 270.10M and a price-to-earnings ratio of 6.27.

Today the stock has traded between $0.2385 and $0.2589. The current price is 2.8% above the day's low and 5.3% below its high.

Volume so far is 742.32K shares, in line with the average of 762.83K shares a day.

Over the past year Elite Pharmaceuticals has ranged from $0.213 to $0.69, and now sits 7% of the way up that range.

Elite Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q4 FY26 it reported $0.00 per share against an estimate of $0.00.

ELTP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 0.0% on average.

  1. Q1 FY25: reported $0.00 per share against an estimate of $0.00
  2. Q2 FY25: reported $0.00 per share against an estimate of $0.00
  3. Q3 FY25: reported -$0.01 per share against an estimate of $0.00
  4. Q4 FY25: reported $0.01 per share against an estimate of $0.00
  5. Q1 FY26: reported -$0.01 per share against an estimate of $0.00
  6. Q2 FY26: reported $0.00 per share against an estimate of $0.00
  7. Q3 FY26: reported $0.01 per share against an estimate of $0.00
  8. Q4 FY26: reported $0.00 per share against an estimate of $0.00

ELTP news

  • Elite Pharmaceuticals Reports Q4 2026 Results: Full Earnings Call Transcript

Similar companies

Companies in the same industry as Elite Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.